Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    October 2017
  1. CARLINO MS, Sandhu S
    Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma.
    J Clin Oncol. 2017 Oct 19:JCO2017752055. doi: 10.1200/JCO.2017.75.2055.
    PubMed     Text format    


  2. CALLAHAN MK, Kluger H, Postow MA, Segal NH, et al
    Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    J Clin Oncol. 2017 Oct 17:JCO2017722850. doi: 10.1200/JCO.2017.72.2850.
    PubMed     Text format     Abstract available


  3. LONG GV, Eroglu Z, Infante J, Patel S, et al
    Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
    J Clin Oncol. 2017 Oct 9:JCO2017741025. doi: 10.1200/JCO.2017.74.1025.
    PubMed     Text format     Abstract available


  4. CHESNEY J, Puzanov I, Collichio F, Singh P, et al
    Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
    J Clin Oncol. 2017 Oct 5:JCO2017737379. doi: 10.1200/JCO.2017.73.7379.
    PubMed     Text format     Abstract available


    September 2017
  5. SZNOL M, Ferrucci PF, Hogg D, Atkins MB, et al
    Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    J Clin Oncol. 2017 Sep 15:JCO2016721167. doi: 10.1200/JCO.2016.72.1167.
    PubMed     Text format     Abstract available


    August 2017
  6. SCHADENDORF D, Wolchok JD, Hodi FS, Chiarion-Sileni V, et al
    Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
    J Clin Oncol. 2017 Aug 25:JCO2017732289. doi: 10.1200/JCO.2017.73.2289.
    PubMed     Text format     Abstract available


    July 2017
  7. LARKIN J, Minor D, D'Angelo S, Neyns B, et al
    Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    J Clin Oncol. 2017 Jul 3:JCO2016718023. doi: 10.1200/JCO.2016.71.8023.
    PubMed     Text format     Abstract available


    June 2017
  8. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Text format     Abstract available


    April 2017
  9. HAYDU LE, Scolyer RA, Lo S, Quinn MJ, et al
    Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
    J Clin Oncol. 2017 Apr 4:JCO2016719393. doi: 10.1200/JCO.2016.71.9393.
    PubMed     Text format     Abstract available


    February 2017
  10. KOHN CG, Zeichner SB, Chen Q, Montero AJ, et al
    Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    J Clin Oncol. 2017 Feb 21:JCO2016696336. doi: 10.1200/JCO.2016.69.6336.
    PubMed     Text format     Abstract available


    January 2017
  11. AGARWALA SS, Lee SJ, Yip W, Rao UN, et al
    Phase III Randomized Study of 4 Weeks of High-Dose Interferon-alpha-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Rese
    J Clin Oncol. 2017 Jan 30:JCO2016702951. doi: 10.1200/JCO.2016.70.2951.
    PubMed     Text format     Abstract available


  12. D'ANGELO SP, Larkin J, Sosman JA, Lebbe C, et al
    Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
    J Clin Oncol. 2017;35:226-235.
    PubMed     Text format     Abstract available


  13. WATTS CG, Cust AE, Menzies SW, Mann GJ, et al
    Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
    J Clin Oncol. 2017;35:63-71.
    PubMed     Text format     Abstract available


    December 2016
  14. POWELL CA
    Pulmonary Infiltrates in a Patient With Advanced Melanoma.
    J Clin Oncol. 2016 Dec 28:JCO2016699793.
    PubMed     Text format     Abstract available


  15. DIENG M, Butow PN, Costa DS, Morton RL, et al
    Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2016;34:4405-4414.
    PubMed     Text format     Abstract available


  16. DAUD AI, Wolchok JD, Robert C, Hwu WJ, et al
    Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    J Clin Oncol. 2016;34:4102-4109.
    PubMed     Text format     Abstract available


    November 2016
  17. NIJSTEN T
    Sunscreen Use in the Prevention of Melanoma: Common Sense Rules.
    J Clin Oncol. 2016;34:3956-3958.
    PubMed     Text format    


  18. WEBER JS, Hodi FS, Wolchok JD, Topalian SL, et al
    Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
    J Clin Oncol. 2016 Nov 14:JCO2015661389.
    PubMed     Text format     Abstract available


    September 2016
  19. GHIASVAND R, Weiderpass E, Green AC, Lund E, et al
    Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study.
    J Clin Oncol. 2016 Sep 12. pii: JCO675934.
    PubMed     Text format     Abstract available


    June 2016
  20. PUZANOV I, Milhem MM, Minor D, Hamid O, et al
    Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
    J Clin Oncol. 2016 Jun 13. pii: JCO671529.
    PubMed     Text format     Abstract available


    May 2016
  21. GOFF SL, Dudley ME, Citrin DE, Somerville RP, et al
    Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
    J Clin Oncol. 2016 May 23. pii: JCO667220.
    PubMed     Text format     Abstract available


    April 2016
  22. SONDAK VK, McIver B, Kanetsky PA
    Vitamin D and Melanoma: What Do We Tell Our Patients?
    J Clin Oncol. 2016 Apr 4. pii: JCO665240.
    PubMed     Text format    


    March 2016
  23. FANG S, Sui D, Wang Y, Liu H, et al
    Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.
    J Clin Oncol. 2016 Mar 21. pii: JCO641357.
    PubMed     Text format     Abstract available


  24. INDINI A, Di Nicola M, Del Vecchio M, De Braud F, et al
    Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.
    J Clin Oncol. 2016;34:1017-8.
    PubMed     Text format    


  25. HORVAT TZ, Adel NG, Dang TO, Momtaz P, et al
    Reply to A. Indini et al.
    J Clin Oncol. 2016;34:1018-9.
    PubMed     Text format    


  26. HODI FS, Hwu WJ, Kefford R, Weber JS, et al
    Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
    J Clin Oncol. 2016 Mar 7. pii: JCO640391.
    PubMed     Text format     Abstract available


    February 2016
  27. WILGENHOF S, Corthals J, Heirman C, van Baren N, et al
    Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    J Clin Oncol. 2016 Feb 29. pii: JCO634121.
    PubMed     Text format     Abstract available


  28. BERWICK M
    Reply to S. Lehrer et al and J.C. Dowdy and R.M. Sayre.
    J Clin Oncol. 2016;34:638-9.
    PubMed     Text format    


  29. WU S, Cho E, Qureshi AA
    Reply to S. Lehrer et al and J.C. Dowdy and R.M. Sayre.
    J Clin Oncol. 2016;34:637-8.
    PubMed     Text format    


  30. MCMASTERS KM, Egger ME, Edwards MJ, Ross MI, et al
    Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biop
    J Clin Oncol. 2016 Feb 8. pii: JCO633776.
    PubMed     Text format     Abstract available


    January 2016
  31. LONG GV, Weber JS, Infante JR, Kim KB, et al
    Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
    J Clin Oncol. 2016 Jan 25. pii: JCO629345.
    PubMed     Text format     Abstract available


  32. PULVIRENTI T, Hong A, Clements A, Forstner D, et al
    Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.
    J Clin Oncol. 2016;34:e17-20.
    PubMed     Text format    


  33. BULLOCH KJ, Narayan D, Ariyan S, Gould Rothberg BE, et al
    Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  34. DOWDY JC, Sayre RM
    Melanoma Risk From Dietary Furocoumarins: How Much More Evidence Is Required?
    J Clin Oncol. 2016 Jan 4. pii: JCOJCO638643.
    PubMed     Text format    


  35. LEHRER S, Green S, Rosenzweig KE
    Melanoma Risk and Citrus Consumption.
    J Clin Oncol. 2016 Jan 4. pii: JCO638254.
    PubMed     Text format    


    November 2015
  36. FANG S, Wang Y, Amos CI, Lee JE, et al
    Reply to Z. Li et al.
    J Clin Oncol. 2015;33:3674-5.
    PubMed     Text format    


  37. CHIOU VL, Burotto M
    Pseudoprogression and Immune-Related Response in Solid Tumors.
    J Clin Oncol. 2015;33:3541-3.
    PubMed     Text format    


    October 2015
  38. MOHR P, Hauschild A, Trefzer U, Enk A, et al
    Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    J Clin Oncol. 2015 Oct 26. pii: JCO.2014.59.6932.
    PubMed     Text format     Abstract available


    September 2015
  39. LAWSON DH, Lee S, Zhao F, Tarhini AA, et al
    Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After C
    J Clin Oncol. 2015 Sep 8. pii: JCO.2015.62.0500.
    PubMed     Text format     Abstract available


    August 2015
  40. HORVAT TZ, Adel NG, Dang TO, Momtaz P, et al
    Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
    J Clin Oncol. 2015 Aug 17. pii: JCO.2015.60.8448.
    PubMed     Text format     Abstract available


  41. LI Z, Feng J, Sun X
    Is C-Reactive Protein a Specific Marker in Melanoma?
    J Clin Oncol. 2015 Aug 3. pii: JCO.2015.62.2696.
    PubMed     Text format    


  42. LAM CJ, Curtis RE, Dores GM, Engels EA, et al
    Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
    J Clin Oncol. 2015 Aug 3. pii: JCO.2014.60.2094.
    PubMed     Text format     Abstract available


    July 2015
  43. MEVES A, Nikolova E, Heim JB, Squirewell EJ, et al
    Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
    J Clin Oncol. 2015 Jul 6. pii: JCO.2014.60.7002.
    PubMed     Text format     Abstract available


    June 2015
  44. BERWICK M
    Dietary Advice for Melanoma: Not Ready for Prime Time.
    J Clin Oncol. 2015 Jun 29. pii: JCO.2015.61.8116.
    PubMed     Text format    


  45. WU S, Han J, Feskanich D, Cho E, et al
    Citrus Consumption and Risk of Cutaneous Malignant Melanoma.
    J Clin Oncol. 2015 Jun 29. pii: JCO.2014.57.4111.
    PubMed     Text format     Abstract available


    May 2015
  46. ANDTBACKA RH, Kaufman HL, Collichio F, Amatruda T, et al
    Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    J Clin Oncol. 2015 May 26. pii: JCO.2014.58.3377.
    PubMed     Text format     Abstract available


  47. GIBNEY GT, Atkins MB
    Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2015 May 11. pii: JCO.2014.60.1807.
    PubMed     Text format    


    March 2015
  48. DAUD AI, Ashworth MT, Strosberg J, Goldman JW, et al
    Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
    J Clin Oncol. 2015;33:1060-6.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: